The company announced that it would begin offering seven proteomic tests at Colorado doctors' practices with up to four more to launch by the end of the year.
The industry organization issued a letter urging the agency to reconsider recent decisions to demand several laboratories stop offering pharmacogenetic testing.
The company's commercial testing continues to focus on patients with identified lung nodules, but the new data is the strongest yet to support a shift to upfront cancer detection.
The company's goal is to serve what it sees as a massive but underaddressed target group: Asian women.
An investigator for the study said that the sensing platform correctly identified all of the patients that were non-responders to anti-PD-1 immunotherapies.
Starting in late 2020, public health insurance is expected to pay for NIPT if a trisomy is suspected and this constitutes an "unacceptable burden" for the pregnant woman.
While some large health systems have developed internal tools for lab test utilization, a number of outside vendors are rolling out solutions of their own.